SCHEMBL3588780

SCHEMBL3588780

CCOC(=O)Cc1c(Cl)ccc2cc(CN(C)C)ccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.40
CYP4A11 Q02928 1/20 0.40
NCEH1 Q6PIU2 1/20 0.39
PRKCB P05771 2/20 0.38
PRKCA P17252 2/20 0.38
PRKCH P24723 2/20 0.38
PRKCE Q02156 2/20 0.38
PRKCQ Q04759 2/20 0.38
PRKCD Q05655 2/20 0.38
KDM4E B2RXH2 2/20 0.38
LMNA P02545 2/20 0.38
L3MBTL1 Q9Y468 3/20 0.37
MAPT P10636 2/20 0.37
HTT P42858 2/20 0.37
ALDH1A1 P00352 1/20 0.37
GLA P06280 1/20 0.37
THRB P10828 1/20 0.37
CASP1 P29466 1/20 0.37
CASP7 P55210 1/20 0.37
ATM Q13315 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL989779 0.92 CYP4F2 (0.40) CYP4F2CYP4A11PRKCBPRKCAPRKCH
Dimethylamine SCHEMBL5206984 0.88 KDM4E (0.39) CYP4F2CYP4A11PRKCBPRKCAPRKCH
SCHEMBL3596009 0.84 AKR1B1 (0.42) NCEH1PRKCBPRKCAPRKCHPRKCE
SCHEMBL3588222 0.83 SLC6A4 (0.46) NCEH1PRKCBPRKCAPRKCHPRKCE
SCHEMBL3586690 0.81 KDM4E (0.42) KDM4ELMNAL3MBTL1MAPTHTT
SCHEMBL3591326 0.79 PTGS2 (0.50) KDM4ELMNAL3MBTL1MAPTHTT
SCHEMBL3591481 0.79 KDM4E (0.40) KDM4ELMNAL3MBTL1MAPTHTT
SCHEMBL27664986 0.79 RAD52 (0.43) CYP4F2CYP4A11NCEH1PRKCBPRKCA
SCHEMBL3588920 0.77 NCEH1 (0.46) NCEH1KDM4ELMNAL3MBTL1MAPT
SCHEMBL857027 0.75 KDM4E (0.47) KDM4ELMNAMAPTALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691861-B2 Indolymaleimide derivatives NOVARTIS AG (CH) 2010-04-06 US disclosed
US-20080234494-A1 Indolylmaleimide Derivatives NOVARTIS AG (CH) 2008-09-25 US disclosed
EP-1709030-B1 INDOLYLMALEIMIDE DERIVATIVES NOVARTIS AG (CH) 2008-04-02 EP disclosed
EP-1709030-A1 INDOLYLMALEIMIDE DERIVATIVES Novartis AG (CH) 2006-10-11 EP disclosed
WO-2005068454-A1 INDOLYLMALEIMIDE DERIVATIVES NOVARTIS AG (CH) 2005-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234494-A1 Indolylmaleimide Derivatives IDH3A, INMT, IDH2 CYP4F2 1971/4885CYP4A11 1603/4885NCEH1 1392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.